Results 11 to 20 of about 822 (144)

Efficacy and Safety of Novel Oral Anti-Cholestatic Agents for Primary Biliary Cholangitis: Meta-Analyses and Systematic Review [PDF]

Pharmaceuticals
Background: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive bile duct damage and cholestasis. While ursodeoxycholic acid (UDCA) is the first-line therapy, approximately 40% of patients have incomplete ...
Eyad Gadour, Bogdan Miutescu, Hiba Bashir, Abubaker Ali, Salem Alanzi, Abdullah A. Al-Shahrani, Aymen Almuhaidb, Shahed Mohamed, Faisal Abaalkhail, Hadi Kuriry, Mohammed Saad AlQahtani   +10 more
doaj   +2 more sources

Perspectives of Indian Gastroenterologists and Hepatologists on Nonalcoholic Fatty Liver Disease Diagnosis and Management: Insights From the Nationwide Web-Based Cross-Sectional DRIVE Survey [PDF]

Interactive Journal of Medical Research
BackgroundNonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), represent an increasing clinical and public health burden in India. Despite their high prevalence, there are limited
Anil Arora, Yogesh Garje, Shagupta Shaikh, Shruti Dharmadhikari, Chintan Khandhedia, Neeraj Markandeywar, Amey Mane, Suyog C Mehta, Ashish Kumar   +8 more
doaj   +2 more sources

Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Non-alcoholic fatty liver disease (NAFLD) is the most common liver-related metabolic disorder in the world, with a global prevalence of 25%.
Reza Afarin, Negar Dinarvand, Bahar Jaberian Asl, Ghazal Orak, Elham Shakerian, Fatemeh Bineshfar, Akram Ahangarpour   +6 more
doaj   +2 more sources

Saroglitazar Versus Simvastatin for Metabolic and Alcohol-Associated Liver Disease (MetALD). [PDF]

Cureus
Individuals with steatotic liver disease who consume significant amounts of alcohol and meet at least one cardiometabolic criterion are classified as having metabolic and alcohol-associated liver disease (MetALD). The efficacy of saroglitazar and simvastatin in this population remains unclear.
Kulkarni A, Gangdany ZM, Ramagundam R, Sharma M, Padaki NR.   +4 more
europepmc   +3 more sources

Peroxisome Proliferator‐Activated Receptor (PPAR) Agonists for Patients With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid (UDCA): A Systematic Review and Meta‐Analysis of Randomized Controlled Trials [PDF]

JGH Open
Objective Peroxisome proliferator‐activated receptor (PPAR) agonists are agents used for patients with primary biliary cholangitis (PBC) who do not respond to conventional agents like ursodeoxycholic acid (UDCA).
Maadeha H. Zaidi, Zaroon Haider, FNU Sadia, Muhammad Tayyab, Muhammad Naveed Tariq, Hasaan H. Ans, Muhammad Bilal Javaid, Ahmad Khan, Muhammad Hassan Ahmad, Rahman Rasheed, Uzair Jafar, Huzaifa Ahmad Cheema, Asma'a Munasar Ali Alsubari, Muhammad Shahzil, Essam Rashad, Rehmat Ullah Awan, Hassam Ali, Prasun K. Jalal   +17 more
doaj   +2 more sources

Healing Effects of Saroglitazar Gel in Thermally Induced Burn in Rats [PDF]

Al-Anbar Medical Journal
Background: Burn is associated with several consequences, including an increased incidence of infection, extended duration of hospitalization, and an increased mortality rate.
Aram Ibrahim, Hawkar Baiz, Zheen Ahmed, Hemn Othman, Tavga Aziz   +4 more
doaj   +2 more sources

The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia

Life and Science
Objective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treating diabetic dyslipidemia. Study Design: Comparative cross-sectional study.
Bakhtawar Farooq, Rafay-Ur-Rehman Cheema, Zahid Habib Qureshi, Nabeela Yasmeen, Ejaz Hussain Sahu   +4 more
doaj   +2 more sources

Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis [PDF]

Clinical and Molecular Hepatology
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a spectrum of pathology involving fatty liver disease that may progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure.
Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz   +4 more
doaj   +2 more sources

PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis [PDF]

Annals of Medicine
Background and aim Lipid accumulation in hepatocytes is reduced by the activation of the peroxisome proliferator-activated receptor (PPAR) α, which is associated with increased lysosomal acid lipase (LAL) activity, transcription factor EB (TFEB ...
Federica Cetti, Alice Ossoli, Carola Garavaglia, Lorenzo Da Dalt, Giuseppe Danilo Norata, Monica Gomaraschi   +5 more
doaj   +2 more sources

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence

Diabetes, Metabolic Syndrome and Obesity, 2015
Aravind Sosale,1 Banshi Saboo,2 Bhavana Sosale11Diacon Hospital, Bangalore, 2Dia Care (Diabetes Care and Hormone Clinic), Ahmedabad, IndiaAbstract: Diabetes mellitus (DM) is one of the most dreaded metabolic disorders in the world today.
Sosale A, Saboo B, Sosale B
doaj   +5 more sources